March 1, 2024 04:02 PM EST
R&D
FDA+

J&J's Janssen nabs new in­di­ca­tion, full ap­proval for can­cer drug Ry­bre­vant

Lia DeGroot

John­son & John­son’s Janssen on Fri­day earned an FDA ap­proval for its can­cer drug Ry­bre­vant (ami­van­tam­ab-vmjw) for the first-line treat­ment of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

Benev­o­len­tAI CEO is out af­ter less than a year on the job

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times